Home > Healthcare > Medical Devices > Diagnostic Devices > U.S. Direct-to-Consumer Genetic Testing Market
U.S. Direct-to-Consumer Genetic Testing Market Size
- Report ID: GMI4368
- Published Date: Jan 2023
- Report Format: PDF
U.S. Direct-to-Consumer Genetic Testing Market Size
U.S. Direct-to-Consumer Genetic Testing Market size was valued at over USD 1.5 billion in 2022 and is poised to grow at over 11% CAGR from 2023 to 2032, driven by the growing occurrence of genetic disorders across the globe.
Growing incidence of genetic diseases such as breast cancer, colon cancer, and achondroplasia is likely to increase the demand for DTC tests. As per US CDC, nearly 264,000 cases of breast cancer are diagnosed in women, and around 2,400 in men, annually in the US. Another estimate from the American Cancer Society Data suggests that the country reported 106,180 new cases of colon cancer in 2022. This has elevated the demand for high-quality DTC genetic tests, that are capable of diagnosing genetic disorders much earlier, which has effectively decreased mortality rates among cancer patients, augmenting industry expansion.
| Report Attribute | Details |
|---|---|
| Base Year: | 2022 |
| U.S. Direct-to-Consumer Genetic Testing Market Size in 2022: | USD 1.5 Billion |
| Forecast Period: | 2023 to 2032 |
| Forecast Period 2023 to 2032 CAGR: | 11% |
| 2032 Value Projection: | USD 4.5 Billion |
| Historical Data for: | 2018 to 2022 |
| No. of Pages: | 60 |
| Tables, Charts & Figures: | 66 |
| Segments covered: | Test Type, Technology and Distribution Channel |
| Growth Drivers: |
|
| Pitfalls & Challenges: |
|
Defects in DTC testing may constrain industry development
Defective DTC genetic tests may pose a major challenge to the U.S. direct-to-consumer genetic testing market by stifling demand for these test kits. A study by Ambry Genetics, a leading genetic tests company, found that these tests may yield 40% false positive results. A higher ratio of incorrect results directly impacts the demand for DTC tests as healthcare providers are growing more cautious about putting patient health at stake. Privacy concerns are also likely to hold back growth as the genome sequencing data obtained through these tests can be released into the public, with companies utilizing it for other purposes.
Frequently Asked Questions (FAQ) :
U.S. Direct-to-Consumer Genetic Testing Market Scope
